{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:31:58Z","timestamp":1789993918605,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s00262-011-1004-8","type":"journal-article","created":{"date-parts":[[2011,3,23]],"date-time":"2011-03-23T11:40:43Z","timestamp":1300880443000},"page":"953-963","source":"Crossref","is-referenced-by-count":68,"title":["Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha"],"prefix":"10.1007","volume":"60","author":[{"given":"Els M. E.","family":"Verdegaal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marten","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara H.","family":"Ramwadhdoeb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"van der Minne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne A. Q. M. J.","family":"van Steijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B. A. G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd H.","family":"van der Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W. R.","family":"Nortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Osanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,24]]},"reference":[{"key":"1004_CR1","first-page":"3","volume":"9","author":"DA Oble","year":"2009","unstructured":"Oble DA, Loewe R, Yu P, Mihm MC Jr (2009) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9:3","journal-title":"Cancer Immun"},{"key":"1004_CR2","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233\u20135239","journal-title":"J Clin Oncol"},{"key":"1004_CR3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1053\/j.seminoncol.2007.09.002","volume":"34","author":"ME Dudley","year":"2007","unstructured":"Dudley ME, Rosenberg SA (2007) Adoptive cell transfer therapy. Semin Oncol 34:524\u2013531","journal-title":"Semin Oncol"},{"key":"1004_CR4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbmt.2003.11.003","volume":"10","author":"EF Posthuma","year":"2004","unstructured":"Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH (2004) Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Biol Blood Marrow Transplant 10:204\u2013212","journal-title":"Biol Blood Marrow Transplant"},{"key":"1004_CR5","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/intimm\/dxg140","volume":"15","author":"G Cangemi","year":"2003","unstructured":"Cangemi G, Morandi B, D\u2019Agostino A, Peri C, Conte R, Damonte G, Ferlazzo G, Biassoni R, Melioli G (2003) IFN-alpha mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome. Int Immunol 15:1415\u20131421","journal-title":"Int Immunol"},{"key":"1004_CR6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00262-009-0701-z","volume":"58","author":"R Mendez","year":"2009","unstructured":"Mendez R, Aptsiauri N, Del CA, Maleno I, Cabrera T, Ruiz-Cabello F, Garrido F, Garcia-Lora A (2009) HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol Immunother 58:1507\u20131515","journal-title":"Cancer Immunol Immunother"},{"key":"1004_CR7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.molimm.2008.09.015","volume":"46","author":"M Gigante","year":"2009","unstructured":"Gigante M, Blasi A, Loverre A, Mancini V, Battaglia M, Selvaggi FP, Maiorano E, Napoli A, Castellano G, Storkus WJ, Gesualdo L, Ranieri E (2009) Dysfunctional DC subsets in RCC patients: Ex vivo correction to yield an effective anti-cancer vaccine. Mol Immunol 46:893\u2013901","journal-title":"Mol Immunol"},{"key":"1004_CR8","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1182\/blood-2008-11-188458","volume":"113","author":"HJ Ramos","year":"2009","unstructured":"Ramos HJ, Davis AM, Cole AG, Schatzle JD, Forman J, Farrar JD (2009) Reciprocal responsiveness to IL-12 and IFN-{alpha} specifies human CD8+ effector versus central memory T cell fates. Blood 113:5516\u20135525","journal-title":"Blood"},{"key":"1004_CR9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00262-008-0578-2","volume":"58","author":"R Bouquie","year":"2009","unstructured":"Bouquie R, Bonnin A, Bernardeau K, Khammari A, Dreno B, Jotereau F, Labarriere N, Lang F (2009) A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes. Cancer Immunol Immunother 58:553\u2013566","journal-title":"Cancer Immunol Immunother"},{"key":"1004_CR10","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1182\/blood-2007-09-113050","volume":"111","author":"CS Hinrichs","year":"2008","unstructured":"Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP (2008) IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111:5326\u20135333","journal-title":"Blood"},{"key":"1004_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mpo.1154","volume":"37","author":"Y Tsuchida","year":"2001","unstructured":"Tsuchida Y, Therasse P (2001) Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 37:1\u20133","journal-title":"Med Pediatr Oncol"},{"key":"1004_CR12","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420","journal-title":"Clin Cancer Res"},{"key":"1004_CR13","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/bjc.1997.597","volume":"76","author":"N Brouwenstijn","year":"1997","unstructured":"Brouwenstijn N, Slager EH, Bakker AB, Schreurs MW, van der Spek CW, Adema GJ, Schrier PI, Figdor CG (1997) Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage. Br J Cancer 76:1562\u20131566","journal-title":"Br J Cancer"},{"key":"1004_CR14","doi-asserted-by":"crossref","first-page":"20126","DOI":"10.1016\/S0021-9258(17)32136-1","volume":"269","author":"GJ Adema","year":"1994","unstructured":"Adema GJ, de Boer AJ, Vogel AM, Loenen WA, Figdor CG (1994) Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem 269:20126\u201320133","journal-title":"J Biol Chem"},{"key":"1004_CR15","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ijc.2910520528","volume":"52","author":"F Brasseur","year":"1992","unstructured":"Brasseur F, Marchand M, Vanwijck R, Herin M, Lethe B, Chomez P, Boon T (1992) Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors [letter]. Int J Cancer 52:839\u2013841","journal-title":"Int J Cancer"},{"key":"1004_CR16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF01246677","volume":"40","author":"E Plaen De","year":"1994","unstructured":"De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De SC, Brasseur F, van der Bruggen P, Lethe B, Lurquin C (1994) Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40:360\u2013369","journal-title":"Immunogenetics"},{"key":"1004_CR17","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/intimm\/dxh275","volume":"17","author":"H Takase","year":"2005","unstructured":"Takase H, Yu CR, Mahdi RM, Douek DC, Dirusso GB, Midgley FM, Dogra R, Allende G, Rosenkranz E, Pugliese A, Egwuagu CE, Gery I (2005) Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals. Int Immunol 17:1131\u20131140","journal-title":"Int Immunol"},{"key":"1004_CR18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/(SICI)1097-0215(19990730)82:3<442::AID-IJC19>3.0.CO;2-Z","volume":"82","author":"CA Aarnoudse","year":"1999","unstructured":"Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI (1999) Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer 82:442\u2013448","journal-title":"Int J Cancer"},{"key":"1004_CR19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","volume":"6","author":"H Ikeda","year":"1997","unstructured":"Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, De Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199\u2013208","journal-title":"Immunity"},{"key":"1004_CR20","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20081356","volume":"205","author":"Y Godet","year":"2008","unstructured":"Godet Y, Moreau-Aubry A, Guilloux Y, Vignard V, Khammari A, Dreno B, Jotereau F, Labarriere N (2008) MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med 205:2673\u20132682","journal-title":"J Exp Med"},{"key":"1004_CR21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ijc.2910390320","volume":"39","author":"M Herin","year":"1987","unstructured":"Herin M, Lemoine C, Weynants P, Vessiere F, Van Pel A, Knuth A, Devos R, Boon T (1987) Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 39:390\u2013396","journal-title":"Int J Cancer"},{"key":"1004_CR22","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0198-8859(99)00124-X","volume":"60","author":"EME Verdegaal","year":"1999","unstructured":"Verdegaal EME, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S (1999) Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient. Hum Immunol 60:1195\u20131206","journal-title":"Hum Immunol"},{"key":"1004_CR23","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-10-0041","volume":"16","author":"MJ Besser","year":"2010","unstructured":"Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16:2646\u20132655","journal-title":"Clin Cancer Res"},{"key":"1004_CR24","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1078-0432.CCR-08-2227","volume":"15","author":"FM Speetjens","year":"2009","unstructured":"Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, Drijfhout JW, van de Velde CJ, Melief CJ, van der Burg SH (2009) Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 15:1086\u20131095","journal-title":"Clin Cancer Res"},{"key":"1004_CR25","doi-asserted-by":"crossref","unstructured":"de Vos-van Steenwijk PJ, Heusinkveld M, Ramwadhdoeb\u00e9 TH, Lowik MJ, van der Hulst JM, Goedemans R, Piersma SJ, Kenter GG, van der Burg SH (2010) An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res 70:2707\u20132717","DOI":"10.1158\/0008-5472.CAN-09-4299"},{"key":"1004_CR26","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","volume":"64","author":"A Jong de","year":"2004","unstructured":"de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH (2004) Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 64:5449\u20135455","journal-title":"Cancer Res"},{"key":"1004_CR27","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1097-0142(19860415)57:8+<1705::AID-CNCR2820571314>3.0.CO;2-U","volume":"57","author":"T Taguchi","year":"1986","unstructured":"Taguchi T (1986) Clinical studies of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer 57:1705\u20131708","journal-title":"Cancer"},{"key":"1004_CR28","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2006.09.0274","volume":"25","author":"H Schmidt","year":"2007","unstructured":"Schmidt H, Suciu S, Punt CJ, Gore M, Gore M, Kruit W, Patel P, Lienard D, von der MH, Eggermont AM, Keilholz U (2007) Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on cancer stage IV melanoma: results of the EORTC 18951 biochemotherapy trial. J Clin Oncol 25:1562\u20131569","journal-title":"J Clin Oncol"},{"key":"1004_CR29","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/ni.1942","volume":"11","author":"C Santo De","year":"2010","unstructured":"De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, Salio M, Middleton M, Cerundolo V (2010) Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol 11:1039\u20131046","journal-title":"Nat Immunol"},{"key":"1004_CR30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1479-5876-8-76","volume":"8","author":"PA Ascierto","year":"2010","unstructured":"Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caraco C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N (2010) Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 8:76\u201388","journal-title":"J. Transl Med"},{"key":"1004_CR31","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1200\/JCO.2002.07.070","volume":"20","author":"MB Lens","year":"2002","unstructured":"Lens MB, Dawes M (2002) Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20:1818\u20131825","journal-title":"J Clin Oncol"},{"key":"1004_CR32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00001622-199603000-00015","volume":"8","author":"SS Agarwala","year":"1996","unstructured":"Agarwala SS, Kirkwood JM (1996) Interferons in melanoma. Curr Opin Oncol 8:167\u2013174","journal-title":"Curr Opin Oncol"},{"key":"1004_CR33","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.4049\/jimmunol.175.10.7046","volume":"175","author":"J Zhou","year":"2005","unstructured":"Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF (2005) Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 175:7046\u20137052","journal-title":"J Immunol"},{"key":"1004_CR34","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1111\/j.1600-0625.2009.01055.x","volume":"19","author":"A Correll","year":"2010","unstructured":"Correll A, Tuettenberg A, Becker C, Jonuleit H (2010) Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination. Exp Dermatol 19:e213\u2013e221","journal-title":"Exp Dermatol"},{"key":"1004_CR35","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","volume":"358","author":"NN Hunder","year":"2008","unstructured":"Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Eng J Med 358:2698\u20132703","journal-title":"N Eng J Med"},{"key":"1004_CR36","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1200\/JCO.2006.07.1100","volume":"24","author":"A Mackensen","year":"2006","unstructured":"Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R (2006) Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24:5060\u20135069","journal-title":"J Clin Oncol"},{"key":"1004_CR37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1078-0432.CCR-08-0783","volume":"15","author":"A Ribas","year":"2009","unstructured":"Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la RP, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ (2009) Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res 15:390\u2013399","journal-title":"Clin Cancer Res"},{"key":"1004_CR38","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1056\/NEJMc081511","volume":"359","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, Dudley ME, Restifo NP (2008) Cancer immunotherapy. N Engl J Med 359:1072","journal-title":"N Engl J Med"},{"key":"1004_CR39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev.iy.13.040195.002553","volume":"13","author":"SR Riddell","year":"1995","unstructured":"Riddell SR, Greenberg PD (1995) Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 13:545\u2013586","journal-title":"Annu Rev Immunol"},{"key":"1004_CR40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2217\/imt.09.6","volume":"1","author":"D Hamilton","year":"2009","unstructured":"Hamilton D, Ismail N, Kroeger D, Rudulier C, Bretscher P (2009) Macroimmunology and immunotherapy of cancer. Immunotherapy 1:367\u2013383","journal-title":"Immunotherapy"},{"key":"1004_CR41","first-page":"413","volume":"23","author":"S Ostrand-Rosenberg","year":"2005","unstructured":"Ostrand-Rosenberg S (2005) CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest 23:413\u2013419","journal-title":"Cancer Invest"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1004-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T16:11:19Z","timestamp":1637424679000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-011-1004-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,24]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["1004"],"URL":"https:\/\/doi.org\/10.1007\/s00262-011-1004-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,24]]}}}